Výsledky vyhledávání - "Masanobu, Shigeta"

Akademický článek

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma

Autor: Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

Publikováno v: Current Urology, Vol 17, Iss 1, Pp 52-57 (2023)

Abstract. Objectives. This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. Marterials and methods. Fifty-eight patients with metastatic renal cell carcinoma

Externí odkaz: https://doaj.org/article/ccdc446a8c8f4b7ea52feff951dbda31

Zobrazit plný text záznamu

Akademický článek

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor

Autor: Jun Teishima, Daiki Murata, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

Publikováno v: Current Urology, Vol 15, Iss 4, Pp 187-192 (2021)

Abstract. Background:. There are various alternative first-line therapeutic options besides tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). To inform therapeutic decision-making for such patients, this study aimed to ide

Externí odkaz: https://doaj.org/article/84641c04523a4c029d5f563adab6a1ad

Zobrazit plný text záznamu

Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first‐line tyrosine kinase inhibitors

Autor: Kenshiro Takemoto, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Yuichi Kadonishi, Mitsuru Kajiwara, Jun Teishima, Koji Mita, Satoshi Maruyama, Masanobu Shigeta, Nobuyuki Hinata

Publikováno v: International Journal of Urology. 30:319-327

To evaluate the significance of both low and high body mass index (BMI) as a biomarker in first-line tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC).The oncological outcome of 235 patients with mRCC treated with TKI from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410f0dd7f3f4aafab9203f9ed0fc62ce
https://doi.org/10.1111/iju.15110

Zobrazit plný text záznamu

Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents

Autor: Jun Teishima, Keisuke Goto, Yohei Sekino, Koji Mita, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Yuichi Kadonishi, Seiji Fujiwara, Kanao Kobayashi, Kousuke Asano, Nobuyuki Hinata

Publikováno v: International Urology and Nephrology. 54:1225-1232

The aim of this study was to investigate prognostic factors and to establish a prognostic model using them for upfront cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitor (IC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77609688c203485207582e7a07b5bd27
https://doi.org/10.1007/s11255-022-03157-w

Zobrazit plný text záznamu

PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma

Autor: Jun Teishima, Daiki Taniyama, Masanobu Shigeta, Takeshi Hagura, Xiangrui Han, Takashi Babasaki, Tetsutaro Hayashi, Kazuya Kuraoka, Keisuke Goto, Shogo Inoue, Kazuhiro Sentani, Akio Matsubara, Wataru Yasui, Yohei Sekino

Publikováno v: Anticancer Research. 40:1943-1951

Background/aim Targeted receptor tyrosine kinase inhibitor (TKI) is a standard treatment in advanced renal cell carcinoma (RCC). However, the role of PTEN in TKI resistance remains poorly understood. We aimed to determine the functional role of PTEN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b908774c5108a64013495cffc7dada7
https://doi.org/10.21873/anticanres.14149

Zobrazit plný text záznamu

Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor

Autor: Kazuma Yukihiro, Jun Teishima, Keisuke Goto, Gaku Aoki, Yohei Sekino, Tetsutaro Hayashi, Yasuhisa Hasegawa, Koji Mita, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Yuichi Kadonishi, Seiji Fujiwara, Nobuyuki Hinata

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 40:455.e11-455.e18

Intermediate risk group of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria is thought to consist of patients with different prognoses. This study investigated the impact of a pretreated modified Glasgow prognosti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bfb31ace6bf0a9e641d614483e4c0d1
https://doi.org/10.1016/j.urolonc.2022.06.016

Zobrazit plný text záznamu

CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

Autor: Kenichiro Ikeda, Masanobu Shigeta, Kenshiro Takemoto, Hiroyuki Kitano, Jun Teishima, Daiki Taniyama, Daiki Murata, Mayumi Kaneko, Kazuya Kuraoka, Keisuke Goto, Naohide Oue, Kazuhiro Sentani, Yohei Sekino, Shogo Inoue, Takashi Babasaki, Tetsutaro Hayashi, Kohei Kobatake, Koji Mita

Publikováno v: Anticancer research. 41(10)

BACKGROUND/AIM Sunitinib continues to be administered as a first-line therapeutic agent in metastatic renal cell carcinoma (mRCC). This study examined the potential role of p53 in sunitinib resistance and as a predictive marker in mRCC. MATERIALS AND

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3696a78ea570ea138116f5418203b80
https://pubmed.ncbi.nlm.nih.gov/34593435

Zobrazit plný text záznamu

P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

Autor: YOHEI SEKINO, KENSHIRO TAKEMOTO, DAIKI MURATA, TAKASHI BABASAKI, KOHEI KOBATAKE, HIROYUKI KITANO, KENICHIRO IKEDA, KEISUKE GOTO, SHOGO INOUE, TETSUTARO HAYASHI, DAIKI TANIYAMA, MASANOBU SHIGETA, KAZUYA KURAOKA, KOJI MITA, MAYUMI KANEKO, KAZUHIRO SENTANI, NAOHIDE OUE, JUN TEISHIMA

Publikováno v: Anticancer research. 41(9)

Sunitinib continues to be administered as a first-line therapeutic agent in metastatic renal cell carcinoma (mRCC). This study examined the potential role of p53 in sunitinib resistance and as a predictive marker in mRCC.We analysed the effects of p5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66be482e31de2b50e641ac5c840e9020
https://pubmed.ncbi.nlm.nih.gov/34475048

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání